Back to search results

CD70.CAR for Lymphoma, Myeloma, and Solid Tumors

This study is testing a new type of treatment called CD70.CAR for patients with lymphoma (lymph gland cancer), myeloma, or solid tumors, including some sarcomas and kidney cancers. These cancers must have returned or not responded to standard treatments and express a protein called CD70. The CD70.CAR treatment uses your own immune cells, called T cells, which are specially modified in the lab to recognize and attack cancer cells that have the CD70 protein. Researchers will collect your blood to create these specialized T cells, which are then given back to you. The main goal is to see how safe the CD70.CAR treatment is by looking at any serious side effects within four weeks after you receive the cells. This study aims to enroll 88 participants.

Study design
This is an interventional study with an unclear status, planning to enroll 88 participants. Participants will be assigned one of four different dose levels of the CD70.CAR treatment.
What's involved
Blood will be collected from you to create the CD70.CAR T cells. After receiving the cells, you will be followed for a total of 15 years to monitor for any long-term side effects.
Compensation
Not stated in the trial record.
Follow-up
You will be followed for 15 years after receiving the treatment to check for long-term side effects of the gene transfer.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07297160

CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors

Not Yet Recruiting
PHASE1Ages 0–75InterventionalTreatment
Baylor College of Medicine
~88 participants
Updated 2026-03-04 on ClinicalTrials.gov
What's tested:Dose Level -1Dose Level 1 (starting dose level)Dose Level 2Dose Level 3

At a glance

Recruiting sites
0 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Dose limiting toxicity (DLT) rate
Measured over 4 weeks post infusion

Conditions

Lymphoma
Myeloma
Solid Tumors
Sarcoma
Kidney Cancer

Explore related trials

Hodgkin's GranulomaMultiple MyelomaRenal Cell CarcinomaSarcomaT-Cell Non-Hodgkin LymphomaCD70 Antigen

Where it's being run

2 sites across 1 states
Texas2

Study leadership

  • Bilal Omer, MD · PRINCIPAL_INVESTIGATOR · Baylor College of Medicine

Who to contact

Bilal Omer, MD
[email protected]
832-826-0860
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

CD70 positive tumor with at least 26% CD70+ tumor cells by immunohistochemistry (staining can be pending at time of procurement)
Age ≤75 years (except for sarcoma: only patients age ≤25 are eligible) NOTE: The first three (3) patients treated on the study will be adults (≥18 years of age)
Hemoglobin ≥ 7.0 g/dL (can be transfused)
If apheresis required to collect blood, PT and aPTT \<1.5x ULN; Serum Creatinine \< 2 x ULN; AST \< 5 x ULN.
CD70 positive tumor with at least 26% CD70+ tumor cells by immunohistochemistry (tissue)
No systemic chemotherapy at least 2 weeks prior to treatment on study and must be recovered from all acute toxic effects of prior chemotherapy at time of treatment
Age ≤75 years. (except for sarcoma: only patients age ≤25 are eligible) NOTE: The first three (3) patients treated on the study will be adults (≥18 years of age).
Hemoglobin ≥ 7.0 g/dL (can be transfused)
Total bilirubin \< 3 times the upper limit of normal
AST/ALT \< 5 times the upper limit of normal
Creatinine \< 2 times the upper limit of normal
Pulse oximetry of \> 90% on room air
Karnofsky or Lansky score of ≥60%
Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after the study is concluded. Male partner should use a condom.
Informed Consent Obtained.

Exclusion

Active infection (bacterial, fungal or viral) requiring ongoing treatment without improvement.
Known active infection with HIV or HTLV (collected blood will be sent for HIV/HTLV testing, separate testing prior to procurement not required). Patients with HIV are eligible if viral load is undetectable on therapy and CD4 count is \>350 mm3.
Active second cancer (except non-melanoma skin cancer or in situ breast cancer or cervical cancer) or other cancer treated ≤ 2 years prior to enrollment
Ongoing treatment with immune suppression for prophylaxis/treatment of GVHD including high dose steroids (e.g., prednisone \> 0.5 mg/kg/day).
Received investigational anti-cancer agents \< 28 days or 5 half-lives, whichever is shorter
Received any tumor vaccines within the previous 6 weeks
Pregnant or lactating
Uncontrolled infection with HIV, or HTLV. Patients with HIV are eligible if viral load is undetectable on therapy and CD4 count is \>350 mm3.
Clinically significant bacterial, fungal, or viral infection requiring ongoing therapy without improvement.
Cardiac abnormalities: Cardiac echocardiography with LVEF\<50%; Cardiac dysfunction NYHA III or IV; Clinically significant pericardial effusion. Confirmation of absence of these conditions must be obtained within 6 months of treatment.
Use of serotherapy with Campath or Anti-Thymocyte Globulin (ATG) within the last 28 days
Use of Donor Lymphocyte Infusion (DLI) or other cellular therapy product within 28 days.
Acute GVHD ≥ Grade 2 or moderate to severe (formerly extensive) chronic GVHD.
High dose steroids \>1 mg/kg within the preceding 5 days or currently receiving \>0.5 mg/kg/day prednisone equivalent.
Bulky CNS or mediastinal disease that significantly increases potential risks (e.g. airway obstruction, TIAN) in the estimation of a principal investigator.

What this trial measures

  • Dose limiting toxicity (DLT) rate4 weeks post infusion

    Toxicity for all patients will be evaluated using the NCI Common Toxicity Criteria Scale with the exception of CRS and immune effector cell associated neurotoxicity (ICANS). CRS and ICANS will be graded per ASTCT consensus grading criteria.